Ireland - English - HPRA (Health Products Regulatory Authority)

medac gesellschaft fur klinische spezialpraparate - levofolinic acid sodium hydroxide - solution for inj/inf - 50 micromol

Ireland - English - HPRA (Health Products Regulatory Authority)

medac gesellschaft fur klinische spezialpraparate mbh - urokinase - powder for solution for infusion - 10,000 international unit(s) - enzymes; urokinase

Ireland - English - HPRA (Health Products Regulatory Authority)

medac gesellschaft fur klinische spezialpraparate mbh - urokinase - powder for solution for infusion - 50,000 international unit(s) - enzymes; urokinase

Ireland - English - HPRA (Health Products Regulatory Authority)

medac gesellschaft fur klinische spezialpraparate mbh - urokinase - powder for solution for infusion - 100,000 international unit(s) - enzymes; urokinase

Ireland - English - HPRA (Health Products Regulatory Authority)

medac gesellschaft fur klinische spezialpraparate mbh - urokinase - powder for solution for infusion - 250,000 international unit(s) - enzymes; urokinase

Ireland - English - HPRA (Health Products Regulatory Authority)

medac gesellschaft fur klinische spezialpraparate mbh - urokinase - powder for solution for infusion - 500,000 international unit(s) - enzymes; urokinase

Ireland - English - HPRA (Health Products Regulatory Authority)

medac gesellschaft fur klinische spezialpraparate mbh - mitomycin - pdr+solv/soln/intravesical use - 20 milligram(s) - other cytotoxic antibiotics; mitomycin

Ireland - English - HPRA (Health Products Regulatory Authority)

medac gesellschaft fur klinische spezialpraparate mbh - bendamustine hydrochloride - pdr/conc/soln for infus - 25 milligram - alkylating agents

Ireland - English - HPRA (Health Products Regulatory Authority)

medac gesellschaft fur klinische spezialpraparate mbh - bendamustine hydrochloride - pdr/conc/soln for infus - 100 milligram - alkylating agents

European Union - English - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - capecitabine - colorectal neoplasms - antineoplastic agents - capecitabine medac is indicated for the adjuvant treatment of patients following surgery of stage-iii (dukes’ stage-c) colon cancer.capecitabine medac is indicated for the treatment of metastatic colorectal cancer.capecitabine medac is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.capecitabine medac in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline.capecitabine medac is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.